fbpx
close read more

About Servier

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

Press contact :

01.55.72.70.10 – presse@servier.com

Press release

Press release
08/11/2016
Servier signs agreement with non-profit association La Chaîne de l’Espoir and announces creation of the Mécénat Servier endowment fund
Press release
20/10/2016
New compound shows promise in treating multiple human cancers
Press release
01/09/2016
Amgen and Servier extend Omecamtiv Mecarbil collaboration in Chronic Heart Failure
Press release
27/07/2016
Servier invests in bioproduction in France
Press release
11/07/2016
Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody
Press release
11/07/2016
Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody
Press release
27/04/2016
Patients with Advanced Metastatic Colorectal Cancer in Europe Now Have a New Treatment Option as LONSURF® (trifluridine/tipiracil) Receives EU Approval
Press release
06/04/2016
40th year of operations in Brazil
Press release
01/04/2016
Withdrawal of fusafungine-containing medicines from the market